Medical treatment of glaucoma and the promising perspectives

Current Opinion in Ophthalmology

Volumn 7, Issue 2, 1996, Pages 18-23

  Diestelhorst, Michael ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIGLAUCOMA AGENT; APRACLONIDINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; DORZOLAMIDE; LATANOPROST; PROSTAGLANDIN F2 ALPHA DERIVATIVE; TIMOLOL;

ALLERGIC CONJUNCTIVITIS; ALLERGIC REACTION; AQUEOUS HUMOR FORMATION; AQUEOUS HUMOR OUTFLOW; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; EYE COLOR; FATIGUE; GLAUCOMA; HUMAN; HYPEREMIA; INTRAOCULAR PRESSURE; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SEDATION; TOPICAL DRUG ADMINISTRATION; XEROSTOMIA;

EID: 0029758315     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-199604000-00004     Document Type: Review

References (56)

1. Sherwood MB, Sharir M, Schultz JS: Initial treatment of Glaucoma: surgery or medications. Surv Ophthalmol 1993, 37:293-305.
2. Vuori ML, Kaila T: Plasma kinetics and antagonist activity of topical ocular timolol in elderly patients. Graefes Arch Clin Exp Ophthalmol 1995, 233:131-134.
3. Passo MS, Palmer EA, Van Buskirk EM: Plasma timolol in glaucoma patients. Ophthalmology 1984, 91:1361-1363.
4. Van Buskirk EM: Adverse reactions from timolol administration. Ophthalmology 1980, 87:448-450.
5. Patel CS, Spaeth GL: Compliance in patients prescribed eyedrops for • glaucoma. Ophthalmic Surg 1995, 26:233-236. The authors describe the difficulties clinicians face with the compliance of their patients.
6. Avorn J, Glynn RJ, Gurwitz JH, Bohn RL, Monane M, Everitt D, Gilden D, Choodnovskiy I: Adverse pulmonary effects of topical β-blockers used in the treatment of glaucoma. J Glaucoma 1993, 2:158-165.
7. Hoskins D, Hetherington J, Minckler D, Liebermann M, Shaffer R: Complications of laser trabeculoplasty. Ophthalmology 1983, 90:796-799.
8. Feist RM, Palmer DJ, Fiscella R, Ernest JT, Tripathi R, Torczynski E, Farber M: Effectiveness of apraclonidine and acetazolamide in preventing postoperative intraocular pressure spikes after extracapsular cataract extraction. J Cataract Refract Surg 1995, 21:191-195.
9. Koskela T, Brubaker R: Apraclonidine and timolol: combined effects in previously untreated normal subjects. Arch Ophthalmol 1991, 109:804-806.
10. Lish A, Camras C, Podos S: Effect of apraclonidine on intraocular pressure in glaucoma patients receiving maximally tolerated medications. J Glaucoma 1992, 1:19-22.
11. Pollack I, Brown R, Crandall A, Steward R, White G: Prevention of the rise in intraocular pressure following neodymium-YAG posterior capsulotomy using topical 1% apraclonidine. Arch Ophthalmol 1988, 106:754-757.
12. Robin A: Short-term effects of unilateral 1% apraclonidine therapy. Arch Ophthalmol 1988, 106:912-915.
13. Toris CB, Tafoya MD, Camras CB, Yablonski ME: Effects of apraclonidine on aqueous humor dynamics in human eyes. Ophthalmology 1995, 102:456-461.
14. Butler P, Mannschreck M, Lin S, Hwang I, Alvarado J: Clinical experience with the long-term use of 1% apraclonidine: incidence of allergic reactions. Arch Ophthalmol 1995, 113:293-296.
15. Stewart WC, Ritch R, Shin DH, Lehmann RP, Shrader CE, Van Buskirk M: The efficacy of apraclonidine as an adjunct to timolol therapy. Arch Ophthalmol 1995, 113:287-292.
16. Becker B: Decrease in intraocular pressure in man by carbonic anhydrase inhibitor: diamox. A preliminary report. Am J Ophthalmol 1954, 37:13-15.
17. Becker B: The mechanism of the fall in intraocular pressure induced by the carbonic anhydrase inhibitor, diamox. Am J Ophthalmol 1955, 39:177-182.
18. Dailey RA, Brubaker RF, Bourne WM: The effects of timolol maleate and acetazolamide on the rate of aqueous formation in normal human subjects. Am J Ophthalmol 1982, 93:232-237.
19. Strahlman E, Tipping R, Vogel R, and the International Dorzolamide Study Group: A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol and betaxolol. Arch Ophthalmol 1995, 113:1009-1016.
20. Wilkerson M, Cyrlin M, Lippa EA, Esposito D, Deasy D, Panebianco D, Fazio R, Yablonski M. Shields MB: Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol 1993, 111:1343-1350.
21. Heitt JA, Dockter CA Topical carbonic anhydrawe inhibitors: a new perspective in glaucoma therapy. Optom Clin 1992, 2:97-112.
22. Diestelhorst M: Comparative potencies of the topical carbonic anhydrase inhibitors MK-417 and MK-927. Invest Ophthalmol Vis Sci 1989, 30:3-23.
23. Lippa EA: MK-507 versus sezolamide: comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology 1991, 98:308-313.
24. Lippa EA, Carlson LE, Ehinger B, Erikson LO, Finnstrom K, Holmin C, Nilsson SEG, Nyman K, Raitta C, Ringvold A, et al.: Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol 1992, 110:495-498.
25. Higginbotham EJ: Topical carbonic anhydrase inhibitors. Ophthalmol Clin North Am 1989, 2:113-130.
26. Ponticello GS, Freedman MB, Habekcer CN: Thienothiopyran-2-sulfonamides: a novel class of water-soluble carbonic anhydrase inhibitors. J Med Chem 1987, 30:591-597.
27. Wang R-F, Serle JB, Podos SM, Sugrue MF: The ocular hypotensive effect of the topical carbonic anhydrase inhibitor L-671 152 in glaucomatous monkeys. Arch Ophthalmol 1990, 108:511-413.
28. Lippa EA, Schuman JS, Higginbotham EJ, et al.: MK-507 vs sezolamide: comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology 1991, 98:308-312.
29. Baldwin J, Ponticello G, Anderson P, et al.: Thienothiopyran-2-sulfonamides. novel topically active carbonic anhydrase inhibitors for the treatment of glaucoma. J Med Chem 1989, 32:2510-2513.
30. Lichter PR, Musch DC, Medzihradsky F, Standard RN: Intraocular pressure effects of carbonic anhydrase inhibitors in primary open-angle glaucoma. Am J Ophthalmol 1989, 107:11-17.
31. Higginbotham EJ, Kass MA, Lippa EA, Batenhorst RL, Panebianco DL, Wilensky JT: MK-927, a topical carbonic anhydrase inhibitor: dose response and duration of action. Arch Ophthalmol 1990, 108:65-68.
32. Serle JB, Lustgarten JS, Lippa EY, Camras CB, Panebianco DL, Podos SM: MK-927, a topical carbonic anhydrase inhibitor: dose response and reproducibility. Arch Ophthalmol 1990, 108:838-841.
33. Diestelhorst M, Bechtetoille A, Lippa E, Brunner-Ferber F, Krieglstein GK: Zur Stereospezifität der Augendrucksenkung eines lokal aplizierbaren Karboanhydrasehemmers. Fortschr Ophthalmol 1990, 87:131-133.
34. Lippa EA, Carlson LE, Ehinger B, Eriksson LO, Finnstrom K, Holmin C, Nilsson SE, Nyman K, Raitta C, Ringvold A: Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol 1992, 110:495-499.
35. Brechue WF, Maren TH: A comparison between the effect of topical and systemic carbonic anhydrase inhibitors of aqueous humor secretion. Exp Eye Res 1993, 57:67-78.
36. Gunning F, Bechetoille A, Lippa EA, Pfeiffer N, Gerling J, Holder D, Clineschmidt C, Buntix A, Brunner-Ferber FL, Grehn F, Greve E: Sezolamide: additivity to timolol twice daily. Eye 1992, 6:525-529.
37. Brechue WF, Maren TH: pH and drug ionization affects ocular pressure lowering of topical carbonic anhydrase inhibitors. Invest Ophthalmol Vis Sci 1993, 34:2581-2587.
38. Wistrand PF: Distribution and function of carbonic anhydrase (CA) isoenzymes in the human eye: relevance for the design of topical CA inhibitors. Proc Int Cong Eye Res 1992, 23:35-41.
39. Brechue WF, Maren TH: Carbonic anhydrase inhibitory activity and ocular pharmacology of organic sulfamates. J Pharmacol Exp Ther 1993, 264:670-675.
40. Aim A, Widengard I, Kjellgren D, Söderström M, Friström, Heijl A, Stjer• schantz: Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 1995, 79:12-16. A controlled study on the additivity of latanoprost and timolol, which demonstrated that latanoprost once daily is at least as effective as a twice daily dose regimen.
41. Aim A, Villumsen J: PhXA34, a new potent ocular hypotensive drug: a study of dose-response relationship and on aqueous humor dynamics in healthy volunteers. Arch Ophthalmol 1991, 109:1464-1468.
42. Diestelhorst M, Roters S: The effect of Latanoprost 50 μg/ml vs 15 • μg/ml on the intraocular pressure and aqueous humor protein concentration in glaucoma patients: a randomized, double-masked comparison with Timolol 0.5% as control. Arch Ophthalmol, submitted. The single dose application of latanoprost 0.005% was superior to the twice daily application of latanoprost 0.0015% and timolol 0.5% bid in reduction of IOP.
43. Nagasubramanian S, Sheth Gp, Hitchings RA, Stjernschantz J: Intraocular pressure-reducing effect of PhXA41 in ocular hypertension: comparison of dose regimens. Ophthalmology 1993, 100:1305-1311.
44. Friström B, Nilsson SEG: Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine: a study on patients with elevated intraocular pressure. Arch Ophthalmol 1993, 111:662-665.
45. Villumsen J, Alm A: The effect of adding prostaglandin F2a isopropylester to timolol in patients with open angle glaucoma. Arch Ophthalmol 1990, 108:1102-1105.
46. Lee PY, Shao H, Camras CB, Podos SM: Additivity of prostaglandin F2 alpha-1-isopropylester to timolol in glaucoma patients. Ophthalmology 1991, 98:1079-1082.
47. Gabelt BT, Kaufman PL: The effect of prostaglandin F2a on trabecular outflow facility in cynomolgus monkeys. Exp Eye Res 1990. 51:87-91.
48. Gabelt BT, Kaufman PL: Prostaglandin F2a increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res 1989, 49:389-402.
49. Kerstetter JR, Brubaker RF, Wilson SE, Kullerstrand LJ: Prostaglandin F2a-1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow. Am J Ophthalmol 1988, 105:30-34.
50. Cheng-Bennett A, Chan MF, Gac T, Garst ME, Gluchowski C, Kaplan LJ, Protzman CE, Roof MB, Wheeler LA, Williams LS. Woodward DF: Studies on a novel series of acyl ester prodrugs of prostaglandin F2a. Br J Ophthalmol 1994, 78:560-567.
51. Toris CB, Camras CB, Yablonski ME: Effects of PhXA41, a new prostaglandin F2a analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993, 100:1297-1304.
52. Nilsson SFE, Samuelsson M, Bill A, Stjernschantz J: Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2a-1-isopropylester in the cynomolgus monkey. Exp Eye Res 1989, 48:707-716.
53. Niloofar Z, Dolan JW, Kacere RD, Brubaker RF: The effects on aqueous dynamics of PhXA41, a new prostablandin F2a analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993, 111:1351-1358.
54. Nagasubramanian S, Sheth GP, Hitchings RA, Stjernschantz J: Intraocular pressure-reducing effect of PhXA41 in ocular hypertension: comparison of dose regimens. Ophthalmology 1993, 100:1305-1311.
55. Hotehama Y, Mishima H: Clinical efficacy of PhXA34 and PhXA41, two novel prostaglandin F2a-isopropyl ester analogues for glaucoma treatment. Jpn J Ophthalmol 1993, 37:259-269.
56. Hotehama Y, Mishima H, Kitazawa Y, Masuda K: Ocular hypotensive effect of PhXA41 in patients with ocular hypertension or primary openangle glaucoma. Jpn J Ophthalmol 1993, 37:270-274.